Automating Ophthalmology Specialty Drug Prior Auth

Navigating **ophthalmology specialty drug prior auth** for high-cost biologics like anti-VEGF injections presents unique challenges for eye care practices. Klivira automates this complex workflow, ensuring timely patient access to critical therapies.

The chronic nature of many retinal conditions, coupled with the high cost and strict payer policies surrounding specialty drugs, makes efficient prior authorization critical. Revenue cycle teams and prior authorization coordinators in ophthalmology face a constant battle against denials and delays. Understanding the nuances of medical versus pharmacy benefit and specific documentation requirements for drugs like anti-VEGFs is paramount.

The Unique Landscape of Ophthalmology Specialty Drug Prior Auth

Ophthalmology practices manage a high volume of specialty drug prior authorizations, predominantly for intravitreal anti-VEGF injections that are foundational for treating conditions like wet AMD and diabetic macular edema. These chronic treatment cycles require periodic re-authorization, often involving complex documentation and precise benefit-side determination—whether the drug falls under the medical or pharmacy benefit.

Key Prior Authorization Triggers in Eye Care

**Anti-VEGF intravitreal injections:** Aflibercept (Eylea, Eylea HD), Ranibizumab (Lucentis), Faricimab (Vabysmo), and Bevacizumab (compounded off-label) for wet AMD, DME, RVO.
**Specialty drops:** High-cost, complex ophthalmic solutions requiring specific medical necessity.
**Premium IOLs:** While standard cataract surgery is often exempt, premium intraocular lenses or specific specialty lens technologies may trigger PA based on payer policy and medical necessity.
**Glaucoma surgical procedures:** Micro-invasive glaucoma surgery (MIGS) and other complex procedures often require PA, with payer policies varying on device approval.
**Corneal cross-linking:** For keratoconus, requiring documentation of diagnosis and disease progression.

Navigating Benefit-Side Determination and Payer Channels

A core challenge in ophthalmology specialty drug PA is accurately classifying whether a drug falls under the medical or pharmacy benefit, as this dictates the submission channel. Pharmacy-benefit drugs route through ePA partners utilizing NCPDP SCRIPT, while medical-benefit drugs require submission via payer portals, X12 278 EDI, or Da Vinci PAS where available. Misclassification leads to immediate denials and delays.

Critical Documentation for Ocular Specialty Drugs

**Diagnosis confirmation:** Supported by objective findings such as OCT showing fluid, and fluorescein angiography (FA) where applicable.
**Visual acuity documentation:** Essential for establishing medical necessity and monitoring treatment response.
**Prior treatment response:** Required for continuing anti-VEGF treatment cycles, demonstrating efficacy and necessity.
**Step therapy compliance:** Documentation of prior-line therapies or rationale for direct access to biologics, including biosimilar substitution considerations.
**Visual field documentation:** Crucial for glaucoma surgery and functional blepharoplasty for ptosis, demonstrating impairment.

Klivira's Approach to Ophthalmology Specialty Drug PA Automation

Klivira's platform addresses the complexities of ophthalmology specialty drug prior auth by automating benefit-side determination per drug, payer, and patient context. Our system routes requests through appropriate channels—NCPDP SCRIPT ePA for pharmacy benefit or X12 278/Da Vinci PAS for medical benefit—while leveraging EMR data to pre-populate forms with AAO-guideline-aware documentation, including OCT findings and treatment histories.

Addressing Common Denial Reasons in Eye Care

Klivira's automation directly targets frequent denial reasons in ophthalmology. This includes logic for biosimilar substitution for anti-VEGFs, ensuring compliance with payer policies, and flagging prior-treatment response gaps for ongoing cycles. Our system also supports accurate documentation for oculoplastic procedures, helping to differentiate between cosmetic and medical necessity, and verifies visual field documentation for glaucoma and ptosis repairs.

Frequently asked questions

How does Klivira handle the medical vs. pharmacy benefit split for ophthalmology specialty drugs?

Klivira's policy engine automatically determines the correct benefit side per drug, payer, and patient context, then routes the PA request through the appropriate channel, whether it's NCPDP SCRIPT ePA for pharmacy benefit or X12 278/Da Vinci PAS for medical benefit.

What specific ophthalmology drugs does Klivira help automate prior authorization for?

Klivira automates prior authorization for high-volume ophthalmology specialty drugs, including anti-VEGF injections such as Aflibercept (Eylea, Eylea HD), Ranibizumab (Lucentis), Faricimab (Vabysmo), and Bevacizumab (off-label compounded), as well as other biologics and specialty drops.

How does Klivira ensure compliance with AAO guidelines for anti-VEGF injections?

Klivira's platform incorporates AAO-guideline-aware workflows, automating the capture of critical documentation like OCT findings, visual acuity, and prior treatment response to support re-authorization cycles for anti-VEGF injections, aligning with established clinical practice patterns.

Can Klivira assist with prior authorization for premium IOLs or oculoplastic procedures?

While the primary focus for specialty drug PA is on biologics, Klivira's platform can support PA for premium IOLs by ensuring medical necessity documentation where applicable. For oculoplastic procedures, it applies logic for cosmetic-vs-medical determination to streamline submissions and reduce denials.

What EMR data does Klivira leverage for ophthalmology prior authorizations?

Klivira integrates with EMRs to extract relevant clinical data, including diagnosis codes, visual acuity, OCT findings, medication history (FHIR MedicationRequest), and treatment response (FHIR Observation resources), to pre-populate PA forms and support step-therapy requirements.